Product
FAB122
2 clinical trials
1 indication
Indication
Amyotrophic lateral sclerosisClinical trial
A Multicenter, Open-label Extension Study to Investigate the Long-term Safety of FAB122 in Patients With Amyotrophic Lateral SclerosisStatus: Terminated, Estimated PCD: 2024-01-09
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of FAB122 in Patients With Amyotrophic Lateral SclerosisStatus: Active (not recruiting), Estimated PCD: 2024-06-20